Annexin A5 in Patients With Severe COVID-19 Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Feasibility Trial
Claudio M. Martin(Western University), Qingping Feng(Lawson Health Research Institute), Fran Priestap, Marat Slessarev(Western University), Douglas D. Fraser(Western University), Brent J. Tschirhart(Western University), Tracey Bentall, Xiangru Lu(Western University), Aleksandra Leligdowicz(University of California, San Francisco), E. Campbell(London Health Sciences Centre), John Basmaji, Tina Mele(Western University), Ian Ball(Western University)
Cited by 5
Related Papers
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
|New England Journal of Medicine|1999|5.2k
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
|Clinical Infectious Diseases|2014|1.1k
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study
|Intensive Care Medicine|2001|984
Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases?
|Critical Care Medicine|2001|597